IS8280A - 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2 - Google Patents

2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2

Info

Publication number
IS8280A
IS8280A IS8280A IS8280A IS8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A
Authority
IS
Iceland
Prior art keywords
benzmide
ylsulfonylamino
cck2
quinoxaline
regulate
Prior art date
Application number
IS8280A
Other languages
English (en)
Inventor
D. Allison Brett
D. Hack Michael
K. Phuong Victor
H. Rabinowitz Michael
D. Rosen Mark
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of IS8280A publication Critical patent/IS8280A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8280A 2003-08-08 2006-01-31 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2 IS8280A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
IS8280A true IS8280A (is) 2006-01-31

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8280A IS8280A (is) 2003-08-08 2006-01-31 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2

Country Status (33)

Country Link
US (3) US7288651B2 (is)
EP (2) EP1651622B1 (is)
JP (2) JP2007501842A (is)
KR (1) KR20060060007A (is)
CN (2) CN1863781A (is)
AR (1) AR045930A1 (is)
AT (2) ATE353322T1 (is)
AU (2) AU2004265312B2 (is)
BR (1) BRPI0413449A (is)
CA (2) CA2534885C (is)
CR (1) CR8229A (is)
CY (1) CY1106486T1 (is)
DE (2) DE602004004663T2 (is)
DK (2) DK1651621T3 (is)
EA (1) EA200600203A1 (is)
EC (1) ECSP066355A (is)
ES (2) ES2281834T3 (is)
HR (1) HRP20080559T3 (is)
IL (1) IL173591A0 (is)
IS (1) IS8280A (is)
LT (1) LT5410B (is)
LV (1) LV13453B (is)
MX (2) MXPA06001550A (is)
NO (1) NO20061122L (is)
NZ (1) NZ545030A (is)
PL (2) PL1651621T3 (is)
PT (2) PT1651621E (is)
SG (1) SG131114A1 (is)
SI (2) SI1651621T1 (is)
TW (1) TW200521120A (is)
UA (1) UA84025C2 (is)
WO (2) WO2005016896A1 (is)
ZA (1) ZA200601946B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001550A (es) * 2003-08-08 2006-09-04 Johnson & Johnson Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de a colecistocinina 2.
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
WO2008108445A1 (ja) 2007-03-07 2008-09-12 Takeda Pharmaceutical Company Limited ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
US8354557B2 (en) * 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
ES2791534T3 (es) * 2012-03-01 2020-11-04 Allergan Inc Derivados de benzofuran-2-sulfonamida como moduladores del receptor de quimiocinas
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
DK3071206T3 (da) 2013-11-22 2021-05-25 CL BioSciences LLC Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
PT945445E (pt) 1996-12-10 2004-01-30 Zeria Pharm Co Ltd Derivados de 1,5-benzodiazepina
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
MXPA06001550A (es) * 2003-08-08 2006-09-04 Johnson & Johnson Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de a colecistocinina 2.
CN101061116A (zh) * 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物

Also Published As

Publication number Publication date
JP2007501841A (ja) 2007-02-01
MXPA06001550A (es) 2006-09-04
LT5410B (lt) 2007-03-26
ES2281834T3 (es) 2007-10-01
IL173591A0 (en) 2006-07-05
NZ545030A (en) 2009-08-28
DE602004015614D1 (de) 2008-09-18
PL1651621T3 (pl) 2009-01-30
DE602004004663T2 (de) 2007-11-22
EP1651622A1 (en) 2006-05-03
PT1651621E (pt) 2008-09-30
CA2534887A1 (en) 2005-02-24
US20080076918A1 (en) 2008-03-27
HRP20080559T3 (en) 2009-01-31
UA84025C2 (en) 2008-09-10
WO2005016897A1 (en) 2005-02-24
CA2534885C (en) 2013-06-04
CR8229A (es) 2008-09-10
CN1863782A (zh) 2006-11-15
ATE403650T1 (de) 2008-08-15
BRPI0413449A (pt) 2006-10-17
WO2005016896A1 (en) 2005-02-24
EA200600203A1 (ru) 2006-08-25
AU2004265312A1 (en) 2005-02-24
ATE353322T1 (de) 2007-02-15
AU2004265312B2 (en) 2010-05-20
US20050043310A1 (en) 2005-02-24
US20050038032A1 (en) 2005-02-17
CN1863781A (zh) 2006-11-15
DE602004004663D1 (de) 2007-03-22
NO20061122L (no) 2006-05-04
ZA200601946B (en) 2007-05-30
US7563895B2 (en) 2009-07-21
KR20060060007A (ko) 2006-06-02
AU2004265311A1 (en) 2005-02-24
DK1651622T3 (da) 2007-05-07
ES2310294T3 (es) 2009-01-01
LT2006017A (en) 2006-11-27
DK1651621T3 (da) 2008-11-10
SI1651621T1 (sl) 2008-12-31
US7288651B2 (en) 2007-10-30
CY1106486T1 (el) 2012-01-25
JP4818110B2 (ja) 2011-11-16
PL1651622T3 (pl) 2007-07-31
EP1651621A1 (en) 2006-05-03
LV13453B (en) 2007-02-20
EP1651621B1 (en) 2008-08-06
AR045930A1 (es) 2005-11-16
SI1651622T1 (sl) 2007-06-30
ECSP066355A (es) 2006-08-30
PT1651622E (pt) 2007-04-30
EP1651622B1 (en) 2007-02-07
SG131114A1 (en) 2007-04-26
CA2534885A1 (en) 2005-02-24
JP2007501842A (ja) 2007-02-01
TW200521120A (en) 2005-07-01
MXPA06001482A (es) 2006-09-04
US7304051B2 (en) 2007-12-04

Similar Documents

Publication Publication Date Title
IS8280A (is) 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS7471A (is) Ný efnasambönd
IS7879A (is) Ný efnasambönd
NO20054005D0 (no) Nye arylpiperazinylforbindelser
SE0302305D0 (sv) Novel Compounds
ATE368042T1 (de) Cephemverbindungen
IS8228A (is) Ný asetídínefnasambönd
HK1086010A1 (en) Ppar active compounds
IS7827A (is) Ný efnasambönd
IS7381A (is) Efnasambönd
IS8089A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
SE0203348D0 (sv) Novel compounds
SE0302368D0 (sv) New compounds
SE0303181D0 (sv) New compounds
SE0303493D0 (sv) New compounds
SE0303078D0 (sv) New compounds
SE0301120D0 (sv) New compounds
SE0301246D0 (sv) New compounds